Pfizer Still Looking To Buy A Tax Advantage – And Before Congress Flips
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer is willing to make a “bold” M&A move, including one that will improve the company’s tax situation, CEO Ian Read told Q3 earnings call, despite the US government’s initiatives to curb tax inversion deals.
You may also be interested in...
Pfizer Oncology Strategy: An Investment Starts To Pay Off
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
When It Comes To A COVID-19 Vaccine For Kids, It Will Be Awhile
US FDA will be cautious about development of a COVID-19 vaccine for children, Commissioner Hahn says at the Financial Times US Pharma And Biotech Summit.
Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold
The US FDA appears to have concerns about the device used to administer the vaccine.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: